Skip to content

Whittier Daily News

66°F
Tuesday, January 27th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Profusa, Inc. - Common Stock (NQ:PFSA)

0.1044 +0.0069 (+7.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Profusa, Inc. - Common Stock

News headline image
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Adds Leading Greek Vascular Surgeon to Customer Base
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
From Profusa, Inc.
Via GlobeNewswire
News headline image
Nika Pharmaceuticals (OTCQB: NIKA) Targets Immune Health Breakthroughs Across HIV, Cancer, and Chronic Diseases
Via AB Newswire
Topics Intellectual Property
News headline image
Peraso Inc. (NASDAQ: PRSO) Taps $15B U.S. Market as Robotaxi Fleets Hit the Fast Lane
Via AB Newswire
News headline image
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35
From Profusa, Inc.
Via GlobeNewswire
News headline image
Santa’s Rally: CMCT, SURG, SIDU, MYSE, AZI – Stocks Under $5 to Watch Now – More Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Announces Third Quarter Business and Financial Highlights
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
From Profusa, Inc.
Via GlobeNewswire
News headline image
Signal Advance (OTC: SIGL) Unveils Breakthrough AI-Resistant Encryption with Analog Guard®, Backed by IBM (NYSE: IBM) – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
From Profusa, Inc.
Via GlobeNewswire
News headline image
Profusa Invests Additional $1 Million in Digital Treasury Assets
From Profusa, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.